{"id":83020,"date":"2020-04-09T00:00:00","date_gmt":"2022-11-09T14:25:14","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/?post_type=eb_course&#038;p=83020"},"modified":"2023-05-02T09:31:01","modified_gmt":"2023-05-02T13:31:01","slug":"advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc","status":"publish","type":"eb_course","link":"http:\/\/www.mdbriefcase.com\/fr\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/","title":{"rendered":"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC"},"content":{"rendered":"<p>Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the <strong>Clinical Oncology Society of Australia (COSA)<\/strong>, focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition in cancer sets the scene, and the program also features case studies and expert videos exploring RCC prognostication, treatment selection and managing the adverse effects of checkpoint inhibitor immunotherapy.<\/p>","protected":false},"featured_media":442001,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-83020","eb_course","type-eb_course","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the Clinical Oncology Society of Australia (COSA), focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T13:31:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/\",\"name\":\"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg\",\"datePublished\":\"2022-11-09T14:25:14+00:00\",\"dateModified\":\"2023-05-02T13:31:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg\",\"width\":600,\"height\":338},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mdbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.mdbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#website\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mdbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\/\/www.mdbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/","og_locale":"fr_CA","og_type":"article","og_title":"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase","og_description":"Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the Clinical Oncology Society of Australia (COSA), focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition [&hellip;]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T13:31:01+00:00","og_image":[{"width":600,"height":338,"url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/","url":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/","name":"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg","datePublished":"2022-11-09T14:25:14+00:00","dateModified":"2023-05-02T13:31:01+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#primaryimage","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/04\/GettyImages-1156991077_LP-1.jpg","width":600,"height":338},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/advances-in-therapy-for-patients-with-intermediate-to-poor-risk-stage-iv-rcc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/83020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=83020"}],"version-history":[{"count":0,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/83020\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/442001"}],"wp:attachment":[{"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=83020"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"http:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=83020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}